SynAct Pharma has announced that its share started trading on Nasdaq Stockholm’s main list July 12, 2022.
“SynAct Pharma has worked hard with its pipeline to make it to where it is today. To be traded on the main market is an important landmark and a stamp of quality for SynAct, which enables us to accelerate the development of our lead candidate drug AP1189 through our clinical programs in RA, NS and other chronic diseases and subsequent commercialization. The move gives us access to more international and institutional investors, who will be key to our ambitious growth plans,” says Jeppe Øvlesen, CEO of SynAct Pharma.
SynAct’s share will be traded in the Mid Cap segment and will retain both its ticker (SYNACT) and ISIN code (SE0008241491). In connection with the list change, there will be no offering or issue of new shares and shareholders of SynAct will not need to take any actions.